Table 2.
Baseline characteristics and comparison stratified by MCT4 score.
| Variables | MCT4 Score 0, n = 46 |
MCT4 Score 1, n = 32 |
MCT4 Score 2, n = 26 |
P between Groups |
|---|---|---|---|---|
| Sex | ||||
| Male, n (%) | 28 (60.9) | 14 (43.8) | 14 (53.8) | 0.329 |
| Age, median (IQR) years | 62 (56–72) | 69 (56–75) | 65 (47–70) | 0.258 |
| T-Class | 0.713 | |||
| T1–2, n (%) | 11 (23.9) | 7 (21.9) | 9 (34.6) | |
| T3, n (%) | 19 (41.3) | 16 (50.0) | 9 (34.6) | |
| T4, n (%) | 16 (34.8) | 9 (28.1) | 8 (30.8) | |
| N-Class | 0.308 | |||
| N0, n (%) | 10 (21.7) | 6 (18.8) | 2 (7.7) | |
| N1–2, n (%) | 36 (78.3) | 26 (81.3) | 24 (92.3) | |
| M-Class | 0.948 | |||
| M0, n (%) | 29 (63.0) | 19 (59.4) | 16 (61.5) | |
| M1, n (%) | 17 (37.0) | 13 (40.6) | 10 (38.5) | |
| Stage | 0.959 | |||
| I–II, n (%) | 6 (13.0) | 3 (9.4) | 2 (7.7) | |
| III, n (%) | 23 (50.0) | 16 (50.0) | 14 (53.8) | |
| IV, n (%) | 17 (37.0) | 13 (40.6) | 10 (38.5) | |
| Grade | ||||
| 1, n (%) | 35 (76.1) | 27 (84.4) | 18 (69.2) | 0.389 |
| 2, n (%) | 11 (23.9) | 5 (15.6) | 8 (30.8) | |
| Tumor location | 0.203 | |||
| Ileum, n (%) | 42 (91.3) | 32 (100) | 25 (96.2) | |
| Jejunum, n (%) | 4 (8.7) | 0 | 1 (3.8) | |
| Somatostatin analogue treatment | ||||
| Yes, n (%) | 24 (52.2) | 20 (62.5) | 16 (61.5) | 0.596 |
| Chemotherapy | 0.669 | |||
| No, n (%) | 35 (76.1) | 27 (84.4) | 24 (92.3) | |
| Preoperative, n (%) | 3 (6.5) | 1 (3.1) | 0 | |
| Postoperative, n (%) | 6 (13.0) | 3 (9.4) | 2 (7.7) | |
| Multiple primary tumors | ||||
| Yes, n (%) | 15 (33.3) | 1 (35.5) | 4 (15.4) | 0.187 |
| P-CgA | ||||
| ≥3 nmol/L, n (%) | 34 (91.9) | 25 (86.2) | 21 (84.0) | 0.609 |
| Median (IQR) nmol/L | 7.6 (4.1–39.5) | 5.0 (3.4–10.2) | 5.5 (3.3–12.0) | 0.209 |
| dU-5-HIAA | ||||
| ≥42 µmol/L, n (%) | 19 (59.4) | 15 (55.6) | 15 (68.2) | 0.658 |
| Median (IQR) µmol/L | 74 (32–266) | 44 (24–104) | 58 (27–222) | 0.258 |
P-CgA, plasma chromogranin A; dU-5-HIAA, 24 h urine hydroxyindoleacetic acid.